Here are our top picks for probiotic supplements for kids and adults alike. Learn the best options for bloating, weight loss, and more.

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

Sleep breathing disorders (SBDs)—including obstructive sleep apnoea, central sleep apnoea and sleep-related hypoventilation syndromes—represent a major yet under-recognised contributor to global ...

Differential pairs in high-speed serial links require tight control of impedance, skew, and coupling to limit reflections, mode conversion, and crosstalk. At multi-gigabit data rates, small deviations ...

The increasing global burden of chronic diseases, coupled with the need for sustainable and health-promoting dietary strategies, has positioned functional ...

Background Immune checkpoint blockade (ICB) has limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC) due to an immunosuppressive tumour microenvironment. Although loss of ...

Phoenix’s mayor wants to make the city a hub for quantum computing. We’ll learn what that is, and how the city can get there. Plus, how one faith tradition aims to help bring down the tone of ...

After testing the all-new 2026 Honda Pioneer 1000 lineup across rugged Texas ranch terrain, we found it more refined, ...

Researchers demonstrated an on-chip method for optically pumping InP nanowire emitters using transfer-printed micro-LEDs, ...

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last ...

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in ...

Following positive first-in-human Phase 1 single ascending dose and preliminary food-effect data with ART26.12, Artelo continues preparations to initiate the multiple ascending dose study, with ...